-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

3427 Reduction in Transplantation Activity without Impairment in Outcomes in the Covid-19 Era- Data from the Sarah Cannon Blood Cancer Network (SCBCN)

Program: Oral and Poster Abstracts
Session: 902. Health Services Research—Malignant Conditions (Lymphoid Disease): Poster III
Hematology Disease Topics & Pathways:
SARS-CoV-2/COVID-19, Coronaviruses, Adult, Therapies, Combinations, Pediatric, Study Population, Clinically relevant, Quality Improvement
Monday, December 7, 2020, 7:00 AM-3:30 PM

Minoo Battiwalla, MD1,2, Carlos Bachier, MD2,3, Vikas Bhushan, MD2,4*, Michael J. Eckrich, MD, MPH2,5, Alireza Eghtedar, MD2,6*, Haydar Frangoul, MD2,7*, Suman Kambhampati, MD2,8*, Shahbaz Malik, MD2,9*, Peter A. McSweeney, MD2,6*, Jeremy Pantin, MBBS2,3, Aravind Ramakrishnan, MD2,9, Hana Safah, MD2,10, Paul J Shaughnessy, MD2,11, Betsy Blunk, BSN, RN, BMTCN2*, Tonya Cox, BSN, RN2, Rocky Billups, MS2 and Charles F. Lemaistre, MD2

1Sarah Cannon Center for Blood Cancer at TriStar Centennial Medical Center, Nashville, TN
2Sarah Cannon Blood Cancer Network, Nashville, TN
3Sarah Cannon Center for Blood Cancer at Tristar Centennial Medical Center, Nashville, TN
4Texas Oncology at Medical City Dallas, Dallas, TX
5Pediatric Blood and Marrow Transplantation Program, Texas Transplant Institute at Medical City Dallas, San Antonio, TX
6Colorado Blood Cancer Institute at Presbyterian/St. Luke's Medical Center, Denver, CO
7Sarah Cannon Cancer Center at Tristar Centennial Medical Center, Nashville, TN
8Sarah Cannon Blood Cancer Center at Research Medical Center, Kansas City, MO
9Sarah Cannon Blood Cancer Center at St. David's South Austin Medical Center, Austin, TX
10Section of Hematology and Medical Oncology, Department of Medicine, Tulane University, New Orleans, LA
11Texas Transplant Institute at Methodist Hospital, San Antonio, TX


The Covid-19 pandemic has profoundly disrupted healthcare operations for vulnerable transplant and cell therapy patients. The Sarah Cannon Blood Cancer Network (SCBCN) comprises six Healthcare Corporation of America hospitals that have been certified based upon defined metrics of infrastructure, staffing, processes and volume. The SCBCN actively coordinated a response by integrating information from the framework of federal, state, network, hospital and individual transplant programs. Dynamic standards were developed taking into account operational aspects (such as PPE conservation, staffing, isolation policy, etc.), external regulations, and input from professional societies in order to balance the needs for life-saving therapy while reducing the likelihood of adverse consequences. In this study, we describe the impact of the Covid-19 across our network on transplant and cell therapy activity as well as the outcomes of the patients who were treated.


Data was integrated from electronic health records and a center survey questionnaire. The period of observation (defined as Covid era) was from March 15, 2020 to June 15th, 2020 to allow sufficient time for analysis of early outcomes. Transplant and cell therapy data from the prior 12 months was used as a comparator.


Within the SCBCN there was a decrease in overall transplant and cell therapy activity in the Covid era. Autologous transplantation was mainly diminished, particularly in the first 2 months. There was no significant impact on allogeneic or CAR-T therapy volumes. For allogeneic transplantation, there was a modest reduction in marrow grafts (11% to 8%) and a significant increase in cryopreservation (16% to 79%, P<0.001). The time to neutrophil and platelet engraftment in the Covid era were similar to those in the prior year. Day +30 survival in the Covid era for allogeneic, autologous, and CAR-T therapy were 95%, 99% and 100%, respectively. Including historically transplanted patients, centers reported a total of 22 patients who contracted proven Covid19, at a median duration of 4 years (range 3-2634 days) post infusion. There were 9-auto, 12-allo, and 1-CAR-T recipients, and two died. Of the two deaths, one 70-year old recipient died from Covid19 after first testing positive at day+3 after autologous transplantation, and another 68-year old recipient tested positive at day+464 after autologous transplantation but died with refractory lymphoma.


We describe a deliberate and coordinated reduction in transplant and cell therapy activity across our network compared to the prior year. For those patients who were selectively transplanted during the Covid19 pandemic, outcomes were not impaired. Our analysis will be updated at the time of presentation with data covering the Covid era from July-Oct ‘20.

Disclosures: Bachier: Sanofi: Speakers Bureau; AlloVir: Honoraria; CRISPR: Honoraria; Juno Therapeutics, a Bristol-Myers Squibb Company: Honoraria. Kambhampati: AbbVie: Other: Investigator in AbbVie-sponsored clinical trials.. McSweeney: Kite, a Gilead Company: Consultancy, Honoraria, Research Funding, Speakers Bureau; Fred Hutchinson: Patents & Royalties; Colorado Blood Cancer Institute: Current Employment. Ramakrishnan: Amgen: Membership on an entity's Board of Directors or advisory committees; Takeda: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Cigna: Honoraria. Safah: Verastem: Honoraria; Astellas: Speakers Bureau; Amgen: Honoraria; Janssen: Speakers Bureau.

*signifies non-member of ASH